ADC Therapeutics SA Short Interest Down 9.7 percent in October
| ADCT Stock | USD 2.15 0.19 8.12% |
Slightly above 60% of ADC Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading ADC Therapeutics SA stock suggests that many investors are alarmed at this time. ADC Therapeutics' investing sentiment can be driven by a variety of factors including economic data, ADC Therapeutics' earnings reports, geopolitical events, and overall market trends.
ADC Therapeutics SA saw a large drop in short interest in October. As of October 31st, there was short interest totalling 3,170,000 shares, a drop of 9.7 percent from the October 15th total of 3,510,000 shares. Based on an average daily volume of 355,600 shares, the short-interest ratio is presently 8.9
Read at thelincolnianonline.com
 |
ADC Therapeutics Fundamental Analysis
We analyze ADC Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
ADC Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ADC Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADC Therapeutics stock to make a market-neutral strategy. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics with similar companies.
Peers
ADC Therapeutics Related Equities
| AKRO | Akero Therapeutics | 24.72 | ||||
| IPSC | Century Therapeutics | 9.09 | ||||
| GBIO | Generation Bio | 5.26 | ||||
| RNA | Avidity Biosciences | 4.70 | ||||
| ALEC | Alector | 4.10 | ||||
| DSGN | Design Therapeutics | 3.97 | ||||
| PASG | Passage Bio | 3.33 | ||||
| BDTX | Black Diamond | 2.84 | ||||
| PTGX | Protagonist Therapeutics | 2.43 | ||||
| STOK | Stoke Therapeutics | 2.24 | ||||
| KURA | Kura Oncology | 2.24 | ||||
| ARVN | Arvinas | 1.68 | ||||
| RARE | Ultragenyx | 1.63 | ||||
| RVMD | Revolution Medicines | 1.35 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.93 | ||||
| ALXO | Alx Oncology | 2.27 |
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.